StockData

TFA Therapeutics, Inc. (RAJAF) stock

RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)

Close on Oct 16, 2026Market cap –P/E –Yield –

TFA Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

TFA Therapeutics's operating income for the twelve months ending Dec 31, 2023 was $227.83K. For fiscal 2025 it was -$141.13K. The highest annual figure on record is $227.83K in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$141.13K–
FY2024Dec 31, 2024-$183.91K-180.7%
FY2023Dec 31, 2023$227.83K–
FY2022Dec 31, 2022-$415.12K–
FY2021Dec 31, 2021-$119.39K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$120.45K–
Q4 FY2022Dec 31, 2022-$36.90K–

More TFA Therapeutics figures

See a number that looks wrong?